This study examined the regulation of leptin production by dexamethasone and troglitazone. Subcutaneous and omental adipose tissue was obtained during bariatric surgical procedures (30 women and 16 men; body mass index, 52.5 Ϯ 1.7 kg/m 2 , age, 39 Ϯ 2 yr), and adipocytes were cultured in suspension. Subcutaneous adipocytes from females released significantly more leptin than did omental cells from the same subject (P Ͻ 0.05), but basal leptin release was not different in adipocytes from these depots in males. Dexamethasone (0.1 mol/L) significantly increased leptin release within 24 h from sc (135 Ϯ 13% of control) and omental (227 Ϯ 53%) adipocytes of females, but not males. Dexamethasone-stimulated leptin production at 48 h was significantly greater in the omental adipocytes of females (398 Ϯ 64% of control) than in sc adipocytes of females (207 Ϯ 21%) or the omental (211 Ϯ 33%) and sc (180 Ϯ 23%) adipocytes of males. Troglitazone (10 mol/L; 48 h) significantly inhibited dexamethasonestimulated leptin release in sc (57 Ϯ 10.7% inhibition) and omental adipocytes (134 Ϯ 26% inhibition). There was no gender-related difference in the effect of troglitazone to inhibit dexamethasone-stimulated leptin release. Troglitazone significantly inhibited basal leptin production from omental adipocytes by 15.0 Ϯ 5.2%. The effect of dexamethasone and troglitazone to regulate leptin release was mediated through changes in ob gene expression, but did not involve changes in glucose uptake or metabolism to lactate.
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The data suggest that adipocytes from females are more responsive to the stimulatory effect of dexamethasone in vitro than are adipocytes from males. If adipocytes from females are more responsive to relevant in vivo stimuli for leptin secretion such as insulin or glucose, this could contribute to the gender difference in serum leptin. The data also suggest that leptin release from omental adipocytes may be more responsive to hormonal and nutrient regulation in vivo than are sc adipocytes. (J Clin Endocrinol Metab 85: 2678 -2684, 2000) S ERUM LEPTIN is highly correlated with adipose tissue mass in humans (1) (2) (3) . However, there is a significant amount of variation in serum leptin for a given amount of body fat in the general population. This variation indicates that leptin is influenced by factors in addition to the amount of adipose tissue. Gender is a major predictor of leptin, and serum leptin levels are significantly higher in females than in males of equivalent fat mass (3) (4) (5) (6) . Gender may influence serum leptin through a direct stimulatory effect of estrogen, or an inhibitory effect of testosterone, on leptin synthesis (7) . The gender-dependent distribution of adipose tissue into either sc or omental depots (7) may also contribute to the variability in serum leptin, as ob gene expression is greater in sc than omental adipose tissue (8 -10) . One additional recently proposed possibility to explain the effect of gender on serum leptin is that adipose tissue from males and females may exhibit a differential response to stimulatory or inhibitory signals for leptin synthesis (11) . This hypothesis is tested in the current studies in vitro, using dexamethasone as a stimulus and troglitazone as an inhibitor of leptin release from cultured human adipocytes.
Dexamethasone is a potent stimulus for leptin secretion in vitro. Dexamethasone increases leptin production from omental adipose tissue pieces (12, 13) , isolated sc adipocytes (14) , and preadipocytes differentiated to adipocytes in culture (15) . It has been reported that dexamethasone can stimulate leptin release in omental adipose tissue pieces obtained from females, but that the glucocorticoid has no effect on leptin release in omental tissue from males (11) . This suggests that a gender-dependent difference in stimulated leptin release may exist.
Troglitazone is a high affinity activating ligand for peroxisome proliferator-activated receptor-␥ (PPAR␥) (16) . This transcription factor is highly expressed in adipocytes and is active in the differentiation of preadipocytes to adipocytes (17) . Troglitazone inhibits ob gene expression and leptin release in rodents and cultured cell lines (18 -21) . In studies in humans, troglitazone significantly improved insulin resistance, but had no effect on serum leptin in two studies (22, 23) and reduced serum leptin in a third study (24) . The direct effect of troglitazone on human adipose tissue leptin production has been examined in only one study, in which it was observed that troglitazone attenuated insulin-stimulated leptin release (22) .
The current studies were conducted to test the hypothesis that leptin synthesis is differentially regulated in sc and omental adipocytes from morbidly obese males and females. Dexamethasone was chosen as a potent stimulus for leptin secretion, and troglitazone was chosen as an inhibitor of leptin production in these studies.
Materials and Methods
Adipose tissue biopsies were obtained from subjects undergoing bariatric surgical procedures. All subjects provided informed consent, and the protocols were approved by the institutional review boards of Indiana University-Purdue University (Indianapolis, IN) and St. Vincent's Hospital (Indianapolis, IN) . Characteristics of the subject population are provided in Table 1 .
Adipocytes were isolated by collagenase (1 mg/mL) digestion as previously described (25) . Isolated adipocytes (2 mL packed cells) were suspension cultured in 10 mL DMEM/Ham's F-12 and 10% FBS in 125-mL polycarbonate flasks at 37 C in 95% O 2 -5% CO 2 . The culture medium contained no insulin, and the concentration of glucose was 1. Leptin was measured using a commercially available RIA kit (Linco Research, Inc., St. Charles, MO). The limit of detection of this assay is 0.5 ng/mL. The within-and between-assay coefficients of variation are 4.6% and 5.0%, respectively, at 7.2 ng/mL. The culture medium containing 10% FBS contained no detectable leptin, nor did it interfere with the detection of added standard human leptin.
Glucose and lactate in the culture medium were measured using a glucose analyzer (model 2300, YSI, Inc., Yellow Springs, OH). Glucose uptake was determined by measuring medium glucose before and after each medium change and calculating the decrease.
ob messenger ribonucleic acid (mRNA) was determined by RT-PCR as previously described (1) . All comparisons between samples were made on the linear portion of the amplification curve (between cycles 20 -35), and no product was obtained in the absence of reverse transcriptase. The data are expressed as the ratio of ob complementary DNA (cDNA) to actin cDNA. There was no difference in the amount of actin cDNA among the samples studied.
All data are expressed as the mean Ϯ sem. The percent inhibition of dexamethasone-stimulated leptin release was calculated by first subtracting basal leptin release from that in the presence of dexamethasone and dexamethasone plus troglitazone. The percent inhibition was then determined by subtracting the ratio of dexamethasone plus troglitazone divided by dexamethasone from 1 and multiplying by 100. All statistical comparisons were made by paired or unpaired t test, using StatView 4.5 (Systat, Evanston, IL) for Macintosh.
Results

Subjects studied
Adipose tissue was obtained from 30 women and 16 men undergoing bariatric surgery. As shown in Table 1 , the body mass index (BMI) of the men was greater than that of the women studied, and the women were slightly younger than the men. The serum leptin level in the women was significantly greater than that in the men at the time the adipose tissue biopsy was taken.
Dexamethasone stimulates leptin production from sc and omental adipocytes
Subcutaneous and omental adipocytes obtained from the same individual were cultured in suspension, and the leptin secreted into the medium was quantitated by RIA. As shown in Table 2 , sc adipocytes continuously release leptin into the medium (basal release at 48 h significantly greater than that at 24 h, P Ͻ 0.05). Culture of sc adipocytes from female subjects with 0.1 mol/L dexamethasone resulted in a significant increase in leptin production over that by untreated cells within the first 24 h of treatment. After 48 h, dexamethasone-stimulated leptin release increased to 207 Ϯ 21% of the control level. In sc adipocytes from male subjects, dexamethasone had no effect on leptin release within the first 24 h, but significantly increased release to 180 Ϯ 23% of the control level by 48 h. There was no significant difference in basal leptin production in sc adipocytes from males and females under these culture conditions. Dexamethasone-stimulated leptin release as a percentage of the basal value was also not different between males and females at 48 h.
As observed for sc adipocytes, omental adipocytes released leptin into the medium continuously over time. Basal leptin release from omental adipocytes of females in the first 24 h of culture was only 64 Ϯ 13% of that from the sc adipocytes isolated from the same subject (P Ͻ 0.05; Table 2 ). There was no difference in basal leptin release between sc and omental adipocytes of males. Dexamethasone significantly increased leptin production in omental adipocytes from females by 24 h (227 Ϯ 53%), and by 48 h, dexamethasone increased leptin production to 398 Ϯ 64% of the control value. In adipocytes from males, dexamethasone had no significant effect on leptin release within the first 24 h of treatment (116 Ϯ 9% of control). After 48 h, dexamethasonestimulated leptin release from omental adipocytes of males was significantly increased to 211 Ϯ 33% of the control level. The stimulatory effect of dexamethasone on leptin production was significantly greater in omental adipocytes from females compared to males (350 Ϯ 46% vs. 194 Ϯ 27% of control; P Ͻ 0.05, unpaired comparison) after 48 h of treatment.
Inhibition of leptin release by troglitazone
Subcutaneous adipocytes were cocultured with 0.1 mol/L dexamethasone and 10 mol/L troglitazone for 48 h. As shown in Fig. 1 , troglitazone significantly inhibited dexamethasone-stimulated leptin release in adipocytes from both males and females at 48 h. The extent of troglitazonemediated inhibition was not significantly different in adi- pocytes from males and females (percent inhibition at 48 h, 49.5 Ϯ 16.8% vs. 62.6 Ϯ 14%). Troglitazone alone had no significant effect on leptin production (5.13 Ϯ 0.85 vs. 5.41 Ϯ 1.30 ng/mL for basal and troglitazone treated, respectively, at 48 h; n ϭ 9). Significant dose-dependent inhibition of dexamethasone-stimulated leptin production by troglitazone could be detected as early as 36 h in cultures of sc adipocytes. At concentrations of 10 and 1 mol/L, troglitazone was equally effective at inhibiting dexamethasonestimulated leptin release (34 Ϯ 10% and 35 Ϯ 13% inhibition; P Ͻ 0.05; n ϭ 6). Troglitazone at 0.1 mol/L had no significant effect on dexamethasone-stimulated leptin release at 36 h. Troglitazone also inhibited leptin production from omental adipocytes in culture. As shown in Fig. 2 , 10 mol/L troglitazone completely inhibited dexamethasone-stimulated leptin production in omental cells at 48 h. Troglitazone was equally effective in inhibiting leptin production in adipocytes from males and females. Troglitazone alone inhibited basal leptin production in omental adipocytes 15.0 Ϯ 5.2% (5.23 Ϯ 1.19 vs. 4.59 Ϯ 1.15 ng/mL for basal and troglitazone-treated leptin production by 48 h; n ϭ 6; P Ͻ 0.05). The effect of troglitazone to inhibit dexamethasone-stimulated leptin production at 48 h was significantly greater in omental (134 Ϯ 26%) than in sc (57 Ϯ 10.7%) adipocytes (P Ͻ 0.005).
Troglitazone inhibited dexamethasone-stimulated leptin release through effects on ob gene expression. As illustrated in Fig. 3 , dexamethasone significantly increased the amount of ob mRNA over that in untreated cells within the first 24 h (P Ͻ 0.05). In the presence of troglitazone, the dexamethasone-induced increase in ob gene expression was attenuated by 55 Ϯ 12% (n ϭ 7; P Ͻ 0.05). These observations suggest that dexamethasone and troglitazone regulate leptin production through effects on ob gene transcription or message stability.
Dexamethasone and troglitazone alter glucose metabolism in human adipocytes
Glucose uptake and metabolism are stimuli for ob gene expression and leptin production in rat adipocytes (26) . We therefore examined glucose uptake and its metabolism to lactate as a mechanism to explain the difference in leptin synthesis between omental and sc adipocytes in females. There was no difference in the amount of glucose taken up (8.7 Ϯ 1.0 vs. 9.4 Ϯ 1.5 mol) or lactate released (7.8 Ϯ 0.6 vs. 8.2 Ϯ 1.4 mol) from paired samples of sc and omental adipocytes, respectively, when examined during the first 24 h (n ϭ 8). It is therefore unlikely that a difference in glucose uptake or metabolism to lactate can account for the difference in basal leptin release between sc and omental adipocytes of females.
Glucose uptake and lactate release were also examined as a mechanism for dexamethasone-and troglitazone-regulated leptin synthesis. In sc adipocytes, dexamethasone significantly decreased glucose uptake (6.9 Ϯ 1.1 vs. 5.8 Ϯ 1.0 mol; P Ͻ 0.01) and lactate release (6.9 Ϯ 0.8 vs. 5.8 Ϯ 0.6 mol; P Ͻ 0.05; n ϭ 6) in the first 24 h. As shown in Table 3 , glucose uptake and lactate production in the presence of dexamethasone continued to be inhibited at 48 h in culture. The combination of dexamethasone and troglitazone did not result in significant inhibition of glucose uptake. Troglitazone alone had no significant effect on glucose uptake or lactate production in sc adipocytes. As observed for the sc adipocytes, dexamethasone significantly decreased glucose uptake (19.4 Ϯ 6.1 vs. 15.3 Ϯ 4.7 mol; P Ͻ 0.05) and lactate release (8.6 Ϯ 1.6 vs. 6.3 Ϯ 0.9 mol; P Ͻ 0.05; n ϭ 7) in omental adipocytes in the first 24 h of culture. As shown in Table 3 , glucose uptake and lactate production in the presence of dexamethasone continued to be inhibited at 48 h in culture. Coincubation of dexamethasone with troglitazone also significantly inhibited glucose uptake and lactate release. Troglitazone alone significantly reduced glucose uptake and lactate release in omental adipocytes at 48 h (Table 3 ).
Discussion
The current study examined the regulation of leptin production by dexamethasone and troglitazone in adipocytes from morbidly obese subjects. Subcutaneous and omental adipocytes from both males and females continuously released leptin into the medium over 48 h. Dexamethasone significantly increased leptin production in adipocytes from both adipose tissue depots from both genders. These observations expand our previous findings in sc adipocytes (14) and extend data obtained from cultured adipose tissue pieces (11) (12) (13) to include isolated omental adipocytes in culture. In addition, we document significant gender-dependent differences in basal and dexamethasone-stimulated leptin production, but not in troglitazone-induced inhibition of leptin release. Finally, we show that troglitazone attenuates leptin production to a greater extent in omental adipocytes than in sc adipocytes.
Basal leptin release from sc adipocytes of females was significantly greater than that from omental adipocytes of females. In contrast, there was no difference in the basal release of leptin from omental and sc adipocytes of males. Several studies using adipose tissue obtained primarily or entirely from females also observed that ob gene expression/ leptin production is greater in sc than omental adipocytes from the same individual (8 -10) . The size of the adipocytes obtained from females in these studies may be important in explaining these observations; ob gene expression is greater in larger adipocytes than in smaller adipocytes isolated from the same piece of adipose tissue (27) , and leptin secretion is strongly correlated with fat cell volume (28) . It has been observed in morbidly obese subjects that sc adipocytes from females are significantly larger than omental adipocytes from the same subject, but there was no difference in the size of omental and sc adipocytes from males (29, 30) . The lack of difference in adipocyte size most likely explains our observation that basal leptin release from sc and that from omental adipocytes from males were the same. In support of this, Montague et al. observed that the ratio of sc to omental adipose tissue ob mRNA was 1.9 Ϯ 0.2 in males vs. 5.5 Ϯ 1.1 in females (8) .
Casabiell et al. (11) recently observed a gender-dependent difference in spontaneous leptin production in omental adipose tissue pieces cultured for 48 h in vitro. In contrast, we did not find a gender-related difference in basal leptin release from isolated sc or omental adipocytes during 48-h cultures. It is possible that the three-dimensional architecture of the adipose tissue pieces was an important determinant of basal leptin production in the study by Casabiell et al. Alternatively, a gender-dependent difference in basal leptin production may be more readily detectable in adipose tissue from normal weight subjects (BMI: females, 27.3 Ϯ 0.8; males, 26.9 Ϯ 0.6 kg/m 2 ) vs. the extremely obese subjects in our study (BMI: females, 48.8 Ϯ 1.4; males, 59.4 Ϯ 3.4 kg/m 2 ). Indeed, although serum leptin is in general 2-to 3-fold greater in females than in males of similar fat mass when examined in a general population, as shown in Table 1 this difference between the genders is attenuated in subjects with extreme obesity. The mechanism resulting in the attenuation of the gender difference in extremely obese subjects is not Adipocytes were cultured in medium containing 7.7 mmol/L glucose for 48 h. Dexamethasone (0.1 mol/L) and troglitazone (Trog; 10 mol/L) were added alone or in combination. Values represent the mean Ϯ SEM for six paired experiments with sc adipocytes (one females and five males) and seven paired experiments with omental adipocytes (three females and four males).
a P Ͻ 0.05, paired comparison to untreated adipocytes.
known. Casabiell et al. (11) also reported that dexamethasone did not stimulate leptin release from omental adipose tissue pieces from males. In contrast, we observed significant dexamethasone-stimulated leptin production from both sc and omental adipocytes from males. An explanation for the discrepancy between the two studies is not readily apparent.
In both sc and omental adipocytes from females, dexamethasone significantly increased leptin release within 24 h. In contrast, a significant effect of dexamethasone on adipocytes from males was not observed until 48 h of treatment. Omental adipocytes from females responded to dexamethasone with a greater fold increase in leptin release over basal than sc adipocytes from females. In contrast, there was no difference in the extent of response between omental and sc adipocytes of males. Although complete dose-response studies to examine the effect of dexamethasone were not performed, Halleux et al. determined that 0.1 mol/L dexamethasone (the concentration used in these studies) is a maximally stimulating dose in omental adipose tissue pieces (12) . These observations, therefore, suggest that adipocytes from females are more responsive to the dexamethasone challenge. If adipocytes from females are more responsive to stimuli for leptin secretion such as insulin or glucose in vivo, this could contribute to the observed gender difference in serum leptin.
One possible explanation for the increased response of adipocytes from females to dexamethasone could be that these adipocytes have more adipose tissue glucocorticoid receptor than adipocytes from males, although there is no evidence to date to support such a hypothesis. However, Rebuffe-Scrive et al. (31) found that omental adipocytes of females contain more glucocorticoid receptor than sc adipocytes of females, thus explaining our observation of greater dexamethasone-stimulated leptin production in omental vs. sc adipocytes from females. A second hypothesis to explain the greater responsiveness of the adipocytes from females is that the cells are preconditioned by exposure to reproductive hormones in vivo. Estrogens have been proposed to stimulate, and androgens to inhibit, leptin synthesis (3) (4) (5) (32) (33) (34) . In vitro, estrogen stimulates leptin release from cultured adipose tissue of both rodents and humans (11, 35, 36) . It is, therefore, possible that exposure to estrogen before adipose tissue biopsy could up-regulate the responsiveness of the cells from the females to dexamethasone. Alternatively, testosterone in males could reduce the subsequent in vitro responsiveness of the adipocytes, although a direct effect of testosterone on ob gene expression was not detected in rodent adipocytes (35, 36) . The mechanism through which the reproductive hormones regulate leptin production remains to be determined.
Troglitazone inhibited dexamethasone-stimulated leptin production to a greater extent in omental adipocytes (134 Ϯ 26%) than in sc adipocytes (57 Ϯ 10.7%). Furthermore, troglitazone significantly inhibited basal leptin release in omental, but not sc, adipocytes. There was no gender-related difference in the effect of troglitazone in either sc or omental adipocytes. These observations suggest that omental adipocytes may be more responsive to troglitazone than are adipocytes from the sc depot. However, no depot-related difference in PPAR␥ mRNA expression was found in a small study of six individuals with BMI greater than 30 kg/m 2 (9) . Additional experiments will be necessary to conclusively determine whether omental adipocytes contain more PPAR␥ than sc adipocytes and whether this results in a greater sensitivity to troglitazone of other metabolic functions of omental adipocytes.
In the current study dexamethasone significantly increased ob gene expression, and troglitazone attenuated the dexamethasone-induced increase in ob gene expression to regulate leptin production. The routine use of dexamethasone to differentiate preadipocytes to adipocytes in vitro (17) raises the possibility that the effects of the glucocorticoid to increase leptin production in primary cultures of adipose tissue explants or isolated cells could be related to the prevention of dedifferentiation during the culture period. This is unlikely based on the observation that dexamethasone increases ob gene expression over that at the time of isolation in omental adipose tissue pieces from humans (12) and isolated rat adipocytes (37) . Thiazolidinediones have been demonstrated to reduce the promoter activity of the human ob gene transfected into rat adipocytes through activation of PPAR␥ (20) . Negative regulation of the ob promoter by the thiazolidinedione AD-5075 maps to the proximal promoter at Ϫ65 to ϩ9, a region that binds C/enhancer binding protein ␣, but not PPAR␥ or retinoid X receptor (21). Hollenberg et al. (21) suggest that thiazolidinediones may act via functional antagonism of C/enhancer binding protein ␣ binding, although the exact mechanism for such an interaction remains to be elucidated. An action of troglitazone to inhibit the ob promoter at a proximal site could explain the ability of this compound to inhibit both dexamethasone-and insulin-induced leptin production (22) .
Glucose uptake and metabolism are important determinants of leptin production in rodent adipocytes in vitro (26) ; however, we did not find a difference in glucose uptake or lactate release in paired samples of sc and omental adipocytes from females. Therefore, depot dependent differences in glucose metabolism to lactate do not appear to account for the difference in leptin synthesis between sc and omental adipocytes. We also found that dexamethasone decreased glucose uptake and lactate production, but increased leptin release in both sc and omental adipocytes. These findings argue against a role for increased glucose uptake as the mechanism by which dexamethasone stimulates leptin production. Troglitazone alone had no effect on glucose uptake or lactate release in sc adipocytes, but significantly attenuated glucose uptake in omental adipocytes. Alterations in glucose uptake and its metabolism to lactate do not appear to be involved in the regulation of leptin production by troglitazone.
In the experiments described in this study we used a pharmacological concentration of dexamethasone as a stimulus, and troglitazone as an inhibitor, of leptin production. One must exercise caution in directly extrapolating our in vitro findings to the regulation of leptin in vivo. Although pharmacological doses of dexamethasone increase serum leptin in humans (38 -42) , infusion of hydrocortisone at normal daily levels in patients with primary adrenal failure had no effect on serum leptin (43) . In this same study reversal of the diurnal pattern of serum cortisol had no effect on serum leptin. Based on these and other observations it does not appear that physiological levels of cortisol directly regulate leptin production. Troglitazone was used in the current studies to inhibit leptin production at a concentration (10 mol/L) slightly higher than the peak serum concentration (6.3 mol/L) attained in humans (44) . Although leptin production is also inhibited by 15-deoxyprostaglandin J2 (45), a putative natural ligand of PPAR␥, there is no evidence to date that regulation of leptin production by PPAR␥ is physiologically relevant in vivo. However, despite the immediate lack of physiological relevance, dexamethasone and troglitazone are valuable tools to understand the mechanisms regulating leptin production.
In summary we have shown that dexamethasone increases leptin production in omental and sc adipocytes from both males and females in vitro. Dexamethasone-induced leptin release occurs more rapidly and is greater in adipocytes from females than in those from males in vitro. This observation suggests that leptin synthesis in females in vivo may be more responsive to stimulatory signals and that this increased responsiveness may contribute to the elevation in serum leptin in women compared to that in men with similar fat mass. Troglitazone attenuates the dexamethasone-induced increase in leptin production in adipocytes from the sc and omental depots of both males and females. The effects of dexamethasone and troglitazone on leptin synthesis occur through alterations in ob gene expression, but not through effects on glucose uptake. The dexamethasone-induced increase in leptin production and the inhibitory effect of troglitazone are both greater in omental than in sc adipocytes in vitro, suggesting that leptin production in this adipose tissue depot may be more responsive to nutrient and hormonal signals in vivo.
